Skip to content
CompoundSci
All briefs

Skin & Longevity

GHK-Cu: The Copper Peptide With Actual Human Data

Where the dermatology evidence is genuinely strong, where the systemic claims collapse, and why formulation decides the outcome.

9 min read
Close-up of blue-tinted laboratory samples under bright light

Want to listen instead of read?

Log in or create a free account to play this narration (about 9 min) and listen to dozens of peptide research briefs, hands free.

Log in to listenCreate a free account

GHK-Cu is one of the few peptides with a real human dataset, because dermatology got there first. It is also routinely oversold. Here is the line between the cosmetic evidence and the systemic claims.

A copper carrier that happens to signal

Glycyl-L-histidyl-L-lysine is a tripeptide found naturally in human plasma, saliva and urine. Its plasma concentration falls roughly 60% between age 20 and age 60. It binds copper(II) with high affinity, and much of its biological activity is the activity of delivered copper, a cofactor for lysyl oxidase, superoxide dismutase and other enzymes central to matrix remodelling.

GHK-Cu

Copper tripeptide-1

Dose
Topical formulations in published trials typically 0.1–2%
Frequency
Once or twice daily topically in cosmetic studies
Route
Topical is the studied route in humans
Half-life
Short in plasma; topical residence is the relevant variable
Storage
Protect from light; copper complexes degrade with oxidation

Systemic injectable use is not supported by human efficacy data.

~60%

Fall in plasma GHK

From age 20 to age 60

70%

Of genes modulated in one expression study

Directional change across 31,000 genes assessed

12 wk

Typical dermatology trial length

Collagen and photodamage endpoints

What the human trials support

  • Improved skin density and reduced fine line depth in controlled topical studies versus vehicle.
  • Wound closure support in chronic wound models, including diabetic ulcer work.
  • Increased collagen and glycosaminoglycan synthesis in fibroblast culture and biopsy endpoints.
Gene expression is a description of what a cell is doing, not evidence that a person got better.

Formulation is most of the result

Copper peptide activity is unusually formulation-sensitive. Vitamin C, alpha hydroxy acids and strong chelators in the same routine will destabilise the complex. Most consumer disappointment with GHK-Cu is a layering problem, not a molecule problem.

Reference

Regenerative and Protective Actions of the GHK-Cu Peptide

Pickart L, Margolina A · International Journal of Molecular Sciences · 2018

The comprehensive review from the researcher who originally isolated GHK.

Reference

Reduction of facial fine lines by a copper tripeptide containing cream

Finkley MB, et al. · International Journal of Cosmetic Science · 2005

Controlled cosmetic trial with photographic and profilometry endpoints.

Frequently asked

Can GHK-Cu be layered with retinol?

Generally yes, though separating them to morning and evening reduces irritation risk and avoids pH conflicts.

Is injectable GHK-Cu supported?

Not by human efficacy data. Copper overload is also a real toxicological concern with systemic administration.

Protocol quizFind your research track

Start a conversation

Debate this

Peptide science moves faster than the consensus around it. Post it with a question and see what people who disagree with you have to say.

Does the research here match what you have seen in practice?

This question is attached to your post, along with a link back to the brief.

Tip: highlight any sentence in the article to debate that exact line.

Read next